2cureX expands distribution of IndiTreat® to Romania

September 1 | 2022

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, today announced the signature of an IndiTreat® distribution agreement for Romania with Onco Systems, a company with strong relationships to the Romanian oncology community.

2cureX and Onco Systems have signed an agreement by which Onco Systems becomes the distributor of IndiTreat® products in Romania. Under the terms of the collaboration, Onco Systems will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and the 2cureX labs in Copenhagen.

The standard treatments used in Romania for colorectal cancer patients are included in the current range of IndiTreat® tests (mCRC Start, mCRC Extend and mCRC Explore), so the guidance provided by IndiTreat® will be relevant for Romanian oncologists.

IndiTreat® now present in 17 countries
“We are delighted to welcome Onco Systems to the network of 2cureX commercial partners. They have strong relationships to the Romanian oncology community, and we are looking forward to the collaboration that will introduce IndiTreat® in their country,” says Fernando Andreu, CEO of 2cureX. “With this agreement, IndiTreat® is now present in 17 countries and, with four more months to go, we are getting closer to the goal of 20 countries by the end of 2022.”

Adding IndiTreat® to Onco Systems oncology portfolio
“We are thrilled to add IndiTreat® to our product portfolio at Onco Systems, as we strongly believe this advanced and innovative diagnostic information will provide Romanian oncologists with a better basis for optimizing their patients’ treatment decisions,” says Grig Coica, Chairman at Onco Systems.

Romania has almost 13,000 new colorectal cancer cases per year
“With a population of 19.4 M people, Romania is one of Europe’s largest countries, and this agreement makes IndiTreat® available to the 13,000 patients that are diagnosed with colorectal cancer (CRC) in the country each year,” says Jesper Floyd Kristiansen, VP Global Business Development at 2cureX. “At the recent ESMO-GI conference we engaged in discussion with several Romanian oncologists who expressed their interest in such a test. We will now be following up these ESMO leads together with our new partner Onco Systems.”

The standard treatments used in Romania for colorectal cancer patients are included in the current range of IndiTreat® tests (mCRC Start, mCRC Extend and mCRC Explore)

The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2023.

About Onco Systems

Onco Systems was established in 2019, with a portfolio of top medical solutions and technologies dedicated to oncological radiotherapy. Onco Systems provides advanced, personalized treatments in order to help oncological patients lead a better and longer life.

Onco Systems is a sister company of the MEDIST group, that includes among othersMEDIST Life Science, MEDIST Imaging and MEDIST Solutions. MEDIST has been a recognized brand in the market of medical equipment suppliers in Romania since 1994.

MEDIST Life Science is already a well-known exclusive distributor in Romania of the largest manufacturers of equipment and reagents for medical and biological research and with strong relation to Romanian pathologists.

For more information about Onco Systems visit: https://www.oncosystems.ro/

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se